San Diego-primarily based Viking Therapeutics marked itself as a significant competitor during the weight loss drug sector in February soon after revealing promising data from the mid-phase demo of experimental drug VK2735, which proposed it rivaled—and outperformed—Novo and Lilly drugs when specified for a weekly injection As well as in March